Thomas P. Gunnarsson

Novo Nordisk (Denmark)1 paperORCID 0000-0001-7414-3045OpenAlex

Papers

Nature MedicineHuman trial

Semaglutide curbs kidney vascular resistance and fibrosis

In 106 people with diabetes and kidney disease, 52 weeks of semaglutide reduced vascular resistance and stabilized markers of fibrosis compared to…In 106 people with diabetes and kidney disease, 52 weeks of semaglutide reduced vascular resistance and stabilized markers of fibrosis compared to placebo.